What Дидрогестерон-гранулы Treats: Main Uses and Benefits

Dydrogesterone-granules is commonly used to provide selective progestational support for several conditions linked to a hormonal imbalance, contributing to functional stability in the reproductive system. The medication is generally applied across domains where additional symptomatic support is needed.

This progestogen is used in the management of conditions characterized by periods of heightened symptoms, including secondary amenorrhea, dysfunctional uterine bleeding, severe dysmenorrhea, and the chronic pelvic pain associated with endometriosis. It is considered relevant for fertility-related issues, such as providing luteal phase support in Assisted Reproductive Technology (ART) and supporting stability in situations involving the risk of threatened or recurrent miscarriage.

In postmenopausal women with an intact uterus, this supportive use is applied to address a systemic imbalance. This helps maintain a sense of stability in the endometrium, which is considered relevant for contributing to a balanced Hormone Replacement Therapy (HRT) regimen. The medicine also plays a role in managing symptom clusters that create noticeable physiological strain, such as incapacitating menstrual pain and endometriosis-related discomfort, contributing to improved comfort during symptomatic periods.

“This supportive function is often utilized when hormonal imbalance results in disruptive symptom manifestations.”

Quick Fact: Therapeutic Focus	Use and Benefit
Symptom Relief	Helps ease incapacitating menstrual pain and chronic pelvic discomfort.
Reproductive Support	Applied for luteal phase support and supporting stability during threatened/recurrent miscarriage.
Cycle Regulation	Assists with managing secondary amenorrhea and dysfunctional uterine bleeding.

Regulatory References

1. Singapore HealthHub overview

Dydrogesterone, a synthetic progestogen, is typically used to treat various conditions caused by progesterone deficiency.

Who Can Use It

It is commonly prescribed for women experiencing:

• Menstrual disorders: Such as painful menstruation (dysmenorrhea), irregular cycles, and Premenstrual Syndrome (PMS).
• Endometriosis (growth of tissue outside the uterus).
• Pregnancy support: Used for threatened or recurrent miscarriage linked to a confirmed progesterone deficiency, and as luteal phase support in assisted reproductive technology.
• Hormone Replacement Therapy (HRT): Combined with estrogen to protect the uterine lining in postmenopausal women with an intact uterus.

---

Who Cannot Use It (Contraindications)

This medication is contraindicated in patients with certain conditions. You should not use Dydrogesterone if you have:

• A known allergy or hypersensitivity to the active substance or any excipients.
• A known or suspected sex hormone-dependent malignancy (e.g., certain tumors like meningioma).
• Undiagnosed vaginal bleeding (the cause must be clarified before use).
• Severe liver disease or a history of severe liver disease until liver function tests have normalized.

Interactions with Other Medicines and Products

Official regulatory information regarding Dydrogesterone focuses on two primary interaction types: those that alter the drug's plasma concentration and those that conflict with the activity of co-administered medicines.

Classification	Interacting Agents / Classes
Reduced Exposure (CYP Inducers)	Rifampicin, Carbamazepine, Phenytoin, Phenobarbital, St John’s Wort
Increased Exposure (CYP Inhibitors)	Ketoconazole, Ritonavir, Clarithromycin
Pharmacodynamic Conflict	Anticoagulants, Conestat alfa
Contraindicated Combination	Estrogens (in combined HRT under specific conditions)

Co-administration with enzyme-inducing agents such as Rifampicin or the herbal product St John’s Wort increases Dydrogesterone metabolism, resulting in a reduced systemic exposure. Conversely, potent enzyme inhibitors such as Ketoconazole may decrease metabolism, potentially increasing the drug’s concentration.

Pharmacodynamic interactions include the potential for Dydrogesterone to decrease the anticoagulant activity of blood-thinning medicines. The combination of Dydrogesterone with Estrogens is formally contraindicated in patients with established active thromboembolic disorders or known thrombophilic states.

Selective Receptor Binding and Intracellular Pathways

Дидрогестерон-гранулы exerts its pharmacologic activity through selective agonism of progesterone receptors (PR), specifically PR-A and PR-B. This interaction initiates a transcriptional cascade: the bound receptor complex translocates to the cell nucleus, where it regulates the expression of target genes. This engagement promotes the modulation of activity within progesterone-responsive pathways.

---

Physiological Consequences

Its progestogenic action results in a complete secretory transformation of the estrogen-primed endometrium, leading to structural changes in the tissue by influencing the processes governing cellular proliferation and differentiation. Furthermore, the compound exhibits a functional antiestrogenic effect in certain tissues. Independently, the drug also demonstrates direct inhibition of myometrial contraction through a rapid, non-genomic, PR-independent pathway, inducing a reduction in the frequency and amplitude of uterine muscle contractions.

How to Use Dydrogesterone Granules — Administration Guidelines

Administration of dydrogesterone, the active ingredient in this medicine, is via the oral route. The fundamental administration protocol dictates specific dosing schedules and frequencies, which are dependent on the condition being addressed.

Administration Scope and Dosing Rules

The medicine is taken with or without food. Dosing ranges for standard maintenance regimens are typically 10 mg to 30 mg per day. For all total daily doses of 20 mg or higher, the dose must be divided and distributed evenly throughout the day to ensure consistent systemic exposure. Lower doses may be taken once daily.

Treatment is commonly prescribed in one of two patterns: a cyclic regimen, where the dose is taken only on specified days of the menstrual cycle (e.g., Day 11 to Day 25), or a continuous regimen for certain types of hormonal support.

Course Duration and Special Conditions

Treatment duration is defined by the specific use. For supporting pregnancy in cases of habitual miscarriage, administration is typically continued up to the 20th week of gestation. For conditions related to infertility due to luteal insufficiency, use is generally maintained for a minimum of three consecutive cycles. Dosing for acute situations, such as threatened miscarriage, begins with an initial 40 mg dose followed by 10 mg every 8 hours, with the maintenance dose continued for one week after symptoms cease, followed by gradual reduction.

Procedural and Age-Group Rules

The protocol for missed doses is as follows: if a scheduled dose is missed by more than 12 hours, the dose must be skipped entirely; the user should not take a double dose to compensate. The safety and efficacy of dydrogesterone have not been established in adolescents (under 18 years), and there is no relevant use before menarche.

Administration Classification	Detail
Route Type	Oral
Frequency Pattern	Daily or Cyclic
Missed Dose Rule	Skip if > 12 hours elapsed

Research Evidence / Overview of Studies for Dydrogesterone-Granules

Research has explored the use of dydrogesterone across several conditions linked to endogenous progesterone deficiency. The evidence base for Assisted Reproductive Technology (ART), such as In Vitro Fertilization (IVF), primarily relies on Randomized Controlled Trials (RCTs) and meta-analyses, which are specific designs used in scientific research. These studies monitored outcomes related to delivery and pregnancy continuation, focusing on the Live Birth Rate (LBR) and the Ongoing Pregnancy Rate. Findings describe patterns observed in the groups that received the oral preparation, often in comparison with other progestogen forms.

---

The research for Threatened Miscarriage and Recurrent Pregnancy Loss (RPL) also includes RCTs and systematic reviews. These studies evaluated the preparation in women experiencing early pregnancy symptoms or those with a history of recurrent loss, monitoring the rate of pregnancy continuation and the recorded incidence of miscarriage. Research highlights changes measured during the study period in groups receiving the preparation, although the consistency of findings is often mixed, and study results show heterogeneity.

---

For conditions such as endometriosis and irregular menstrual cycles (cycle regularization), the evidence structure is different, relying more heavily on Observational Studies and post-marketing data. Studies explored outcomes related to physical discomfort (pain scores) for endometriosis, and patterns in achieving a regular cycle. A key limitation across the entire evidence landscape is the duration of follow-up. Research indicates that the overall certainty level is low for several areas due to the structure of the available evidence, and there is limited information regarding long-term outcomes or recurrence rates after treatment.

Common questions about Дидрогестерон-гранулы (FAQ)

---

Q: Can Dydrogesterone Granules be taken to correct the menstrual cycle?

According to official product information, dydrogesterone is indicated for the management of conditions associated with progesterone insufficiency. These conditions include menstrual disorders such as irregular menstrual cycles and dysmenorrhoea (painful menstruation).

---

Q: What should be done if a dose of Dydrogesterone Granules is missed?

Official administration rules state a clear procedure for missed doses. If a scheduled dose is missed by more than 12 hours, the dose must be skipped entirely according to official protocol. If the lapse is less than 12 hours, the guidance specifies that the dose may be taken as soon as the lapse is noticed. Users should not take a double dose to compensate.

---

Q: At what age can Dydrogesterone Granules be prescribed?

Regulatory documents indicate that the safety and effectiveness of this medicine in adolescents aged 12 to 18 years have not been fully established. Furthermore, the product information states there is no relevant use of the medicine before menarche (the start of the menstrual period).

---

Q: Is it safe to drive while taking Dydrogesterone Granules?

Caution is advised regarding operating machinery or driving, as the official product information lists some potential side effects that may impair concentration. These effects include dizziness and somnolence (drowsiness). If these effects are experienced, activities requiring concentration, such as driving or operating machinery, should be avoided.

---

Q: How long can this medication be taken without a break?

The duration of treatment is determined by the specific condition being addressed. For example, official guidelines specify that use for luteal insufficiency should continue for at least three consecutive cycles. For pregnancy support, administration may be continued up to the 20th week of gestation.

---

Q: Can the granules cause an allergic reaction?

Yes, regulatory data indicates that hypersensitivity reactions are possible, although they are uncommon. These may include allergic skin reactions like a rash, pruritus (itching), or urticaria (hives). The medicine is contraindicated in patients with a known hypersensitivity to the active substance or any excipients.

---

Q: Why is 'spotting' or 'smearing' sometimes observed when taking the granules?

Official safety data lists menstrual irregularities as a common side effect of dydrogesterone. This can include breakthrough bleeding or spotting. This type of mild, irregular bleeding is a known possible effect of the medication, particularly in the early phases of treatment.

---

Q: What should be done in case of an overdose of Dydrogesterone Granules?

Regulatory information suggests that dydrogesterone has a very low toxicity profile, meaning serious effects from an overdose are unlikely. Symptoms such as nausea, vomiting, lethargy, or dizziness may theoretically occur. Official guidance states that no specific treatment is necessary; symptomatic treatment may be considered if needed.

---

Q: Do Dydrogesterone Granules interact with vitamins or supplements?

Official information explicitly warns of interactions with certain herbal products (like St John’s Wort) which can reduce the effectiveness of dydrogesterone. Regarding supplements or vitamins, official sources indicate that patients should discuss co-administration with a healthcare professional, as these may also impact how the medicine works.

---

Q: What is the maximum duration of treatment with Dydrogesterone Granules?

The maximum duration depends heavily on the condition for which the medicine is prescribed. For pregnancy support, treatment is typically limited to the 20th week of gestation. When used as part of Hormone Replacement Therapy (HRT), official guidelines recommend using the lowest effective dose for the shortest duration consistent with treatment goals.

---

Q: How should the intake of Dydrogesterone Granules be stopped without causing harm?

The medication should not be discontinued without consultation with the prescribing doctor. For certain indications, the product information indicates that treatment must be gradually reduced (tapered) after symptoms have ceased.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of this medication, primarily focused on maintaining its chemical stability and protecting the environment.

Requirement Area	Official Constraint
Temperature	Do not store the product above 30 C (Store below 30 C).
Protection	Must be kept protected from moisture and direct light.
Container	Store only in the original receptacle and keep the container tightly closed.
Child Safety	Must be stored out of the sight and reach of children.
Disposal	Do not dispose of in household trash or wastewater; dispose according to local pharmaceutical waste regulations.

The storage constraints, including the maximum temperature of 30 C and mandatory protection from environmental factors, ensure the product remains stable through its labeled shelf-life. Due to environmental hazard warnings, unused or expired medication must be handled only through official pharmaceutical waste procedures.